Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 3 - Decisiondx Diffdx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Decisiondx Diffdx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Decisiondx Diffdx Today - Breaking & Trending Today
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx-Melanoma Tested Patients Compared to Untested Patients
In a recent study, patients diagnosed with melanoma and tested with DecisionDx-Melanoma had improved survival (27% improvement in melanoma-specific survival) compared to untested patients.
Source: pressreleasepoint.com
Castle Biosciences : Reports Fourth Quarter and Full-Year 2021 Results - Form 8-K
Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations ... | March 1, 2022
Source: marketscreener.com
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx . A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.
Source: pressreleasepoint.com
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program Share Article LOS ANGELES (PRWEB) May 06, 2021 MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, today announced that Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, has been selec...
Source: prweb.com